The Severity of Bone Loss in Cushing’s Diseases-Reference-Cited by-同舟云学术

The Severity of Bone Loss in Cushing’s Diseases

Published:2024-04-02 Issue:1 Volume:9 Page:13-21
ISSN:2640-1371
Container-title:International Journal of Diabetes and Endocrinology
language:en
Short-container-title:IJDE

Author:

Debbah Wissame¹,Mezoued Mouna²,Bouzid Aicha²,Talhi Randa³,Bessaid Khadidja²,Azzouz Malha²

Affiliation:

1. Department of Endocrinology and Metabolism, Benyoucef Benkhedda University, Algiers, Algeria

2. Department of Endocrinology and Metabolism, Benyoucef Benkhedda University, Algiers, Algeria; Research Laboratory of Endocrinolgy and Métabolism (LEM 1), Algiers University, Algiers, Algeria

3. Department of Epidemiology, Benyoucef Benkhedda University, Algiers, Algeria

Abstract

Introduction: Endogenous Cushing's syndrome (CS) is a known cause of secondary osteoporosis, characterized by a loss of bone mass and density. Cushing's osteopathy is one of it’s most severe complications. Abnormal bone turnover, decreased bone mineral density (BMD), and increased fracture risk are common effects of glucocorticoid excess. Objectives: The aim of our work is to determine the bone densitometric profile of patients followed for Cushing's disease, to define the characteristics of osteoporosis and osteopenia in these patients, and to analyze the factors influencing BMD. Materials and methods: This is a retrospective descriptive study involving patients followed for Cushing's disease in the endocrinology-diabetology department of the public hospital establishment (EPH) of Bologhine-Algiers, during a period of 10 years, going from the January 2013 to January 2023. Results: 58 patients were followed during this period with an average age was 34 years, with a clear female predominance and a sex ratio of ≈ 4. Average Z score was (-1.6) at the vertebral level and (-1.09) at the femoral level. Osteoporosis was found in 44.8% (n = 26) patients and osteopenia in 37.9% (n = 22), while normal BMD was found in 17.24% (n = 10). Note that Z-score values were significantly lower at the lumbar spine than at the femoral neck. No significant difference in BMD was found between eumenorrheic and hypo-/amenorrheic females with Cushing's disease. Our study demonstrated a significant negative correlation between morning plasma cortisol and BMD. While there is a significant positive correlation between BMD and ACTH concentration in CD patients, BMD at the lumbar spine and femoral neck also had a significant positive correlation with weight and BMI. Conclusion: Early detection and management of CS are essential to reduce bone complications. BMD examinations should be performed to enable rapid recognition and intervention for osteoporosis. Lumbar bone loss occurs earlier and more extensively.

Publisher

Science Publishing Group

Link

https://article.sciencepublishinggroup.com/pdf/j.ijde.20240901.12

Reference34 articles.

1. H. Boro et al., “Trabecular bone score and bone mineral density as indices of skeletal fragility in endogenous Cushing’s syndrome,” Clin Endocrinol, 2023, https://doi.org/10.1111/cen.14944

2. E. J. Ross and D. C. Linch, “Cushing’s syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis,” Lancet, vol. 320, no. 8299, pp. 646–649, 1982. https://doi.org/10.1016/S0140-6736(82)92749-0

3. F. Manelli and A. Giustina, “Glucocorticoid-induced osteoporosis,” Trends Endocrinol. Metab., vol. 11, no. 3, pp. 79–85, 2000. https://doi.org/10.1016/S1043-2760(00)00234-4

4. P. Vestergaard et al., “Increased risk of osteoporotic fractures in patients with Cushing’s syndrome,” Eur. J. Endocrinol., vol. 146, no. 1, pp. 51–56, 2002. https://doi.org/10.1530/eje.0.1460051

5. A. Tabarin et al., “Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing’s syndrome,” in Annales d’endocrinologie, Elsevier, 2022, pp. 119–141. https://doi.org/10.1016/j.ando.2022.02.001